BIO - Bio-Rad Laboratories to acquire Curiosity Diagnostics for $170M

• Bio-Rad Laboratories ( NYSE: BIO ) said Wednesday it will acquire Curiosity Diagnostics from Scope Fluidics, a Polish biotechnology firm, for up to $170M.
• The deal amount consists of ~$100M in cash and up to $70M in future milestone payments.
• Curiosity Diagnostics, a late-stage pre-commercial platform company, is currently developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market.
• "Curiosity's PCR platform PCR|ONE offers a streamlined workflow and rapid turnaround times, and is expected to extend our reach beyond high-complexity labs into near-patient molecular diagnostics labs," said Dara Wright, BIO's EVP and president, Clinical Diagnostics Group.

For further details see: